To include your compound in the COVID-19 Resource Center, submit it here.

Histogenics completes enrollment in Phase III of NeoCart implant

Histogenics Corp. (NASDAQ:HSGX) said it completed enrollment of 245 patients in a Phase III trial of its NeoCart cell therapy implant

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE